Research studies and recruitment
Please email OPA with requests for research recruitment listings - listing rate is $100 CAD for 1 year.
Exploring a potential new treatment for agitation in Alzheimer's disease
This is a study by CAMH, the leading mental health research hospital in Canada. Learn more about what's involved in participating in a study at CAMH Research Connect.
To learn more or ask about joining our study, please call 416-583-1350 or email email@example.com.
CAMH is part of an international study exploring a potential new treatment for agitation in people who have Alzheimer’s disease.
Treatment options for agitation in Alzheimer’s disease are limited. The S-CitAD study is a clinical trial sponsored by the National Institute on Aging (NIA) in the U.S. The study is examining if a prescription medication called escitalopram combined with psycho-social therapy can help reduce agitation. The therapy involves meeting with a trained health care professional and discussing activities, techniques and strategies that can help improve your well-being and day-to-day functioning.
Updated May 2023